In 8 cases (50%), the relapse/metastasis maintained the same immunohistochemical characteristics [i.e. the same hormone receptors (HR) and HER2 status] of the primary tumor, whereas 8 (50%) changed during progression. This evidence concerns the gene ERBB2 and neoplasm.